Your browser doesn't support javascript.
loading
Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
Respondek, Gesine; Grimm, Max-Joseph; Piot, Ines; Arzberger, Thomas; Compta, Yaroslau; Englund, Elisabet; Ferguson, Leslie W; Gelpi, Ellen; Roeber, Sigrun; Giese, Armin; Grossman, Murray; Irwin, David J; Meissner, Wassilios G; Nilsson, Christer; Pantelyat, Alexander; Rajput, Alex; van Swieten, John C; Troakes, Claire; Höglinger, Günter U.
Afiliação
  • Respondek G; Department of Neurology, Technische Universität München, Munich, Germany.
  • Grimm MJ; German Center for Neurodegenerative Diseases, Munich, Germany.
  • Piot I; Department of Neurology, Technische Universität München, Munich, Germany.
  • Arzberger T; German Center for Neurodegenerative Diseases, Munich, Germany.
  • Compta Y; Department of Neurology, Technische Universität München, Munich, Germany.
  • Englund E; German Center for Neurodegenerative Diseases, Munich, Germany.
  • Ferguson LW; Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Gelpi E; Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Roeber S; Parkinson's Disease & Movement Disorders Unit, Hospital Clínic/August Pi i Sunyer Biomedical Research Institute (IDIBAPS)/Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas(CIBERNED)/European Reference Network for Rare Neurological Diseases/Institut de Neurociències,
  • Giese A; Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden.
  • Grossman M; Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatchewan, Canada.
  • Irwin DJ; Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Centres de Recerca de Catalunya (CERCA), Barcelona, Catalonia, Spain.
  • Meissner WG; Institute of Neurology, Medical University of Vienna, Vienna, Austria.
  • Nilsson C; Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Pantelyat A; Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Rajput A; Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • van Swieten JC; Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Troakes C; Univ. de Bordeaux, Institut des Maladies Neurodégénératives, Unité Mixte de Recherche (UMR), 5293, 33000, Bordeaux, France.
  • Höglinger GU; Service de Neurologie, Hôpital Pellegrin, Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000, Bordeaux, France.
Mov Disord ; 35(1): 171-176, 2020 01.
Article em En | MEDLINE | ID: mdl-31571273
BACKGROUND: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category "probable 4-repeat (4R)-tauopathy" for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. OBJECTIVES: To validate the accuracy of these clinical criteria for "probable 4R-tauopathy" to predict underlying 4R-tauopathy pathology. METHODS: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). RESULTS: We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of "probable 4R-tauopathy" was 10% and 99% in the first year and 59% and 88% at final record. CONCLUSIONS: The new diagnostic category "probable 4R-tauopathy" showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers. © 2019 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Paralisia Supranuclear Progressiva / Encéfalo / Transtornos Parkinsonianos / Tauopatias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Paralisia Supranuclear Progressiva / Encéfalo / Transtornos Parkinsonianos / Tauopatias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article